Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743145 · ClinicalTrials.gov registry record · Phase 2
Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00743145 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 23 participants.
The verdict
NCT00743145, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
In heavy marijuana smokers, opioid receptor blockade increases the subjective and cardiovascular effects of marijuana. The current study was designed to clarify opioid-cannabinoid interactions by assessing how naltrexone shifts the dose-response function for marijuana-elicited effects in heavy marijuana smokers. For this within-subject, double-blind study, a marijuana smoking procedure was designed to characterize a dose-response relationship for marijuana's subjective and cardiovascular effects under blinded conditions.
Interventions
- DRUG Naltrexone
- DRUG Inactive Marijuana (0% THC)
- DRUG Active Marijuana (5.5% THC)
- DRUG Active Marijuana (6.2% THC)
- DRUG Placebo naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00743145
The ClinicalTrials.gov registry entry for NCT00743145 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Naltrexone is the first listed.
NCT00743145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00743145 about?
NCT00743145 is a clinical study titled "Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana". In heavy marijuana smokers, opioid receptor blockade increases the subjective and cardiovascular effects of marijuana. The current study was designed to clarify opioid-cannabinoid interactions by assessing how naltrexone shifts the dose-response function for marijuana-elicited effects in heavy marij...
What is the current status of trial NCT00743145?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2008-05. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00743145?
The interventions under investigation include: Naltrexone (DRUG), Inactive Marijuana (0% THC) (DRUG), Active Marijuana (5.5% THC) (DRUG), Active Marijuana (6.2% THC) (DRUG), Placebo naltrexone (DRUG).
Who is sponsoring clinical trial NCT00743145?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.